Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials

OBJECTIVE: To develop a multivariable model assessing factors predicting a second‐dose response to eptinezumab treatment over weeks 13–24 in patients with migraine initially reporting a suboptimal response over weeks 1–12. BACKGROUND: Eptinezumab is a monoclonal antibody used for migraine prevention...

Descripción completa

Detalles Bibliográficos
Autores principales: Schim, Jack D., Anderson, Carlton, Brunner, Elizabeth, Hirman, Joe, Ogbru, Annette, Cady, Roger, McGill, Lora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321567/
https://www.ncbi.nlm.nih.gov/pubmed/35524405
http://dx.doi.org/10.1111/head.14302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321567/
https://www.ncbi.nlm.nih.gov/pubmed/35524405
http://dx.doi.org/10.1111/head.14302

Ejemplares similares